AI Vivo

Combining systems pharmacology and AI to accelerate drug discovery

First Investment: 2019

Current-day drug discovery is inefficient because the focus on molecular targets misses the underlying cellular- and tissue-level dynamics of disease. AI Vivo’s Organome technology ranks drug candidates based on their phenotypic effects at the tissue level. In 2020 the company’s platform correctly predicted that dexamethasone, a commonly prescribed steroid, would save the lives of Covid-19 patients 10 weeks before researchers publicized this outcome.

Explore Companies

Newleos Therapeutics

Transforming the treatment of anxiety and other neuropsychiatric disorders

Grove Biopharma

Putting protein-like drugs inside cells to fight cancer and neurodegeneration

Syntax Bio

Programming stem cells to differentiate into desired cell types, faster

Fable Therapeutics

Using state-of-the-art machine learning models to create custom-build protein drugs